Rapid Micro Biosystems (RPID) Gains from Sales and Divestitures (2022)

Rapid Micro Biosystems' (RPID) quarterly Gains from Sales and Divestitures came in at $82967.0 in Q2 2022, up 23.08% quarter-over-quarter from $67411.0 in Q1 2022.

Rapid Micro Biosystems (RPID) Gains from Sales and Divestitures (2022) Analysis & Trends

Rapid Micro Biosystems has disclosed Gains from Sales and Divestitures across 1 years of filings, most recently posting $82967.0 for Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Rapid Micro Biosystems 77.24 Mn 54.29 Mn 371,000.00

Historic Data

Download Data
DateValue
Jun 30, 2022 82,967.00
Jun 30, 2022 82,967.00
Mar 31, 2022 67,411.00
Mar 31, 2022 67,411.00